Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia
- 24 May 2004
- journal article
- review article
- Published by Springer Nature in Oncogene
- Vol. 23 (24) , 4284-4296
- https://doi.org/10.1038/sj.onc.1207779
Abstract
The RUNX1/AML1 gene is the most frequent target for chromosomal translocation in leukemia. In addition, recent studies have demonstrated point mutations in the RUNX1 gene as another mode of genetic alteration in development of leukemia. Monoallelic germline mutations in RUNX1 result in familial platelet disorder predisposed to acute myelogenous leukemia (FPD/AML). Sporadic point mutations are frequently found in three leukemia entities: AML M0 subtype, MDS-AML, and secondary (therapy-related) MDS/AML. Therapy-related leukemias resulting from anticancer treatments are not uncommon, and the incidence of RUNX1 point mutations appears comparable to the incidence of the t(8;21) AML M2 subtype and the inv(16) AML M4Eo subtype. Half of the point mutations in M0 cases are biallelic, although the frequency varies with ethnicity. Most of the RUNX1 mutations are clustered in the Runt domain and result in defective DNA binding but active -subunit binding, which is consistent with three-dimensional structural findings and may explain the dominant inhibitory effects. Unlike the classical tumor suppressor genes requiring biallelic inactivation, haploinsufficient RUNX1 is apparently leukemogenic. However, RUNX1 abnormalities per se are insufficient to cause full-blown leukemia. Intensive investigation of cooperating genetic alterations should elucidate leukemic mechanisms.Keywords
This publication has 40 references indexed in Scilit:
- Association of CBFA2 mutation with decreased platelet PKC-θ and impaired receptor-mediated activation of GPIIb-IIIa and pleckstrin phosphorylation: proteins regulated by CBFA2 play a role in GPIIb-IIIa activationBlood, 2004
- Lymphoid Enhancer Factor-1 Links Two Hereditary Leukemia Syndromes through Core-binding Factor α Regulation of ELA2Published by Elsevier ,2004
- AML1/RUNX1 mutations are infrequent, but related to AML‐M0, acquired trisomy 21, and leukemic transformation in pediatric hematologic malignanciesGenes, Chromosomes and Cancer, 2003
- Identification of RUNX1/AML1 as a classical tumor suppressor geneOncogene, 2003
- AML-1 mutations outside the RUNT domain: description of two cases in myeloid malignanciesLeukemia, 2002
- Mutation of the AML1/RUNX1 gene in a transient myeloproliferative disorder patient with Down syndromeLeukemia, 2002
- Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion geneNature Genetics, 1997
- Homonucleotide tracts, short repeats and CpG/CpNpG motifs are frequent sites for heterogeneous mutations in the Neurofibromatosis type 1 (NF1) tumour-suppressor geneMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1997
- AML1, the Target of Multiple Chromosomal Translocations in Human Leukemia, Is Essential for Normal Fetal Liver HematopoiesisCell, 1996
- Inherited platelet‐storage pool deficiency associated with a high incidence of acute myeloid leukaemiaBritish Journal of Haematology, 1991